This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TYME Tyme Technologies (TYME) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Tyme Technologies Stock (NASDAQ:TYME) 30 days 90 days 365 days Advanced Chart Get Tyme Technologies alerts:Sign Up Key Stats Today's Range$0.29▼$0.3250-Day Range$0.24▼$0.3552-Week Range$0.22▼$1.14Volume2.68 million shsAverage Volume1.01 million shsMarket Capitalization$53.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.Read More… Receive TYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tyme Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address TYME Stock News HeadlinesTyme é avaliado em US$ 1,5 bi com apoio do Nubank, na ÁfricaDecember 18, 2024 | bloomberg.comBrazil’s Nubank invests $150 million in Tyme Group to expand digital banking offeringsDecember 18, 2024 | msn.comDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profitable miners selling at deep discounts. I call this price gap the Golden Anomaly — and I’ve put together a full report on my top four picks. June 5, 2025 | Golden Portfolio (Ad)Brazilian bank Nubank makes a big R2.7bn investment in fintech Tyme GroupDecember 18, 2024 | msn.comSouth African Tyme Group Becomes Africa’s Latest Unicorn After $250M Series D FundingDecember 18, 2024 | msn.comBrazilian fintech Nubank’s $150mn investment to give South Africa’s Tyme unicorn statusDecember 17, 2024 | ft.comAfrican digital bank Tyme raises $250M round led by Nubank at $1.5B valuationDecember 17, 2024 | msn.comDigital bank Tyme gains unicorn status with $250m Series D raiseDecember 17, 2024 | finance.yahoo.comSee More Headlines TYME Stock Analysis - Frequently Asked Questions How were Tyme Technologies' earnings last quarter? Tyme Technologies, Inc. (NASDAQ:TYME) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.03) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.03. Read the conference call transcript. What other stocks do shareholders of Tyme Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tyme Technologies investors own include NIO (NIO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Tonix Pharmaceuticals (TNXP), SCYNEXIS (SCYX) and Company Calendar Last Earnings11/08/2021Today6/04/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TYME CIK1537917 Webwww.tymeinc.com Phone(212) 461-2315FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.63 million Net MarginsN/A Pretax MarginN/A Return on Equity-28.30% Return on Assets-26.21% Debt Debt-to-Equity RatioN/A Current Ratio14.06 Quick Ratio14.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book0.66Miscellaneous Outstanding Shares172,207,000Free Float143,104,000Market Cap$53.50 million OptionableOptionable Beta0.93 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:TYME) was last updated on 6/5/2025 by MarketBeat.com Staff From Our PartnersDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredJunior Explorer Taps Into TSMC’s $165 Billion Chip CorridorThe chip war is moving underground. As the U.S. ramps up semiconductor production to outpace China, an unex...Capital Trends | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crash...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tyme Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tyme Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.